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Abstract
Background: The consumption of chocolate and cocoa has established cardiovascular benefits. Less is known about the effects of chocolate on arterial stiffness, a marker of subclinical
cardiovascular disease. The aim of this study was to investigate whether chocolate intakes are
independently associated with pulse wave velocity (PWV), after adjustment for cardiovascular,
lifestyle and dietary factors. Methods: Prospective analyses were undertaken on 508 community-dwelling participants (mean age 61 years, 60% women) from the Maine-Syracuse Longitudinal Study (MSLS). Habitual chocolate intakes, measured using a food frequency questionnaire, were related to PWV, measured approximately 5 years later. Results: Chocolate intake
was significantly associated with PWV in a non-linear fashion with the highest levels of PWV
in those who never or rarely ate chocolate and lowest levels in those who consumed chocolate
once a week. This pattern of results remained and was not attenuated after multivariate adjustment for diabetes, cardiovascular risk factors and dietary variables (p = 0.002). Conclusions: Weekly chocolate intake may be of benefit to arterial stiffness. Further studies are
needed to explore the underlying mechanisms that may mediate the observed effects of ha© 2016 S. Karger AG, Basel
bitual chocolate consumption on arterial stiffness.
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Introduction

The consumption of chocolate is widespread throughout the world, with particularly
high intakes in the United States [1]. With a rich natural complexity, it is commonly associated
with pleasure and enjoyment, as well as having a wide-ranging number of medicinal benefits
[2, 3]. More recent scientific interest has been directed at the cardiovascular benefits derived
from chocolate and cocoa consumption [4–6]. Flavonoids, naturally occurring polyphenolic
compounds present in plant-based foods, represent up to 20% of the compounds present in
cocoa beans [7] and may be responsible for the benefits to cardiovascular function [4].
Flavanols, in particular epicatechin, are the most common subgroup of flavonoids, and are the
most common cocoa flavonoids [7]. High levels of flavanols are also found in tea, red wine and
fruits such as grapes and apples [8, 9].
The majority of vascular studies examining cocoa/chocolate have focused on their associations with endothelial function. The antioxidant properties of flavonoids [4] have been
used to explain the demonstrated improvements in flow-mediated dilation of the brachial
artery as a result of cocoa [10–13] or chocolate [14] consumption in healthy adults. Fewer
studies have examined associations between chocolate or cocoa products and arterial
stiffness. Arterial stiffness is higher in persons with diabetes mellitus, obesity and other
cardiovascular risk factors and increases with blood pressure (BP) and age [15, 16]. It is a
major risk factor for myocardial infarction, stroke, end-stage renal disease and other cardiovascular diseases (CVD) [17–19]. Observational cross-sectional findings with regard to
cocoa/chocolate intakes and arterial stiffness have been inconsistent to date [20, 21]. Similarly, a few randomized trials examining the short-term effects on arterial stiffness from chocolate/cocoa consumption ranging from a single dose to daily consumption over a number of
weeks have shown mixed results [22–25]. We have not identified any cohort studies that have
examined associations between longer-term habitual chocolate intake over a period of years
and measures of arterial stiffness. Using data collected from participants of wave 6 and 7 in
the Maine-Syracuse Longitudinal Study (MSLS), the aim of the present study was to determine
whether habitual chocolate intakes were associated with arterial stiffness, with control for
cardiovascular, lifestyle and dietary factors.

Materials and Methods
Participants
The MSLS was a community-based study of cardiovascular risk factors and cognitive functioning in
community-living adults [26, 27]. The MSLS consists of five cohorts defined by time of entry into the study
(1975–2000). At initial recruitment, participants were living independently in Syracuse, N.Y., and were not
being seen as patients. All subjects were accepted into the study regardless of health status. The only exclusions at recruitment were diagnosis of or treatment for psychiatric illness, alcoholism and inability to
comprehend English.
Dietary data were collected for the first time at wave 6 (2001–2006), and pulse wave velocity (PWV)
data were obtained for the first time at wave 7 (2006–2010). This allowed for a prospective design in which
chocolate intakes at wave 6 (baseline) were used to predict PWV at wave 7. The mean time between waves
6 and 7 was 4.7 ± 0.6 years. Eight-hundred and twenty-two subjects were invited back to the laboratory for
testing at wave 7. Six-hundred and nine participants returned and completed PWV data collection. Participants were excluded for the following reasons: before or at wave 6 having missing data for health variables
(n = 58), history of acute stroke (n = 28), probable dementia (n = 8), undertaking renal dialysis treatment
(n = 5), inability to read English (n = 1) and prior alcohol abuse (n = 1), leaving a sample of 508 study participants.
Stroke, defined as a focal neurological deficit of acute onset persisting for more than 24 h, was based on
self-report and was confirmed by a record review indicating a diagnosis of acute stroke. Clinical diagnoses
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of dementia were determined from cognitive data and medical records using the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria [28] and confirmed using the ICD-10 Guidelines [29].
This study was conducted according to the guidelines established by the Declaration of Helsinki, and all
procedures were approved by the University of Maine Institutional Review Board. Written informed consent
was obtained from all subjects.
Assessment of Dietary Intake
Dietary intake was assessed using the Nutrition and Health Questionnaire, including a widely validated
food frequency questionnaire [30, 31]. Participants were required to stipulate how frequently they consume
a list of foods, including meat, fish, eggs, breads, cereals, rice and pasta, fruit, vegetables, dairy foods, chocolate, nuts, other snack-type foods and beverages, including tea, coffee, water, fruit juice and alcohol. Participants were required to stipulate how frequently they consume each food, from six response options: never,
seldom, once/week, 2–4 times/week, 5–6 times/week and once or more per day. Chocolate was not differentiated according to type, i.e. dark, milk, or white chocolate.
In order to estimate mean intakes of the major food groups and total energy intake, the median score
within each response option was used to estimate total intakes per week; for example, 2–3 times per week
was estimated at 2.5. The mean number of times each food was consumed on a weekly and then daily basis
was calculated for all foods in the questionnaire. As portion sizes were not stipulated to participants, these
totals are an estimate of the number of times each food was consumed on a daily basis. Individual foods were
categorized into five major food groups – grains, fruits, vegetables, protein foods and dairy foods – based on
the USDA Food Guide Pyramid [32]. Intakes of individual foods and beverages within each food group were
summed to give an estimate of total intake for each group. An estimation of total energy intake was calculated
by adding intakes of all food groups, and was used to control for energy intake in subsequent analyses.
BP and PWV Assessment
Automated BP measures (GE DINAMAP 100DPC-120XEN, GE Healthcare) were taken in the right arm
five times each in recumbent, standing and sitting position after a supine rest for 15 min, and the 15 values
were averaged for systolic BP (SBP) and diastolic BP (DBP). Mean arterial pressure (MAP) was calculated
using the following: DBP + (1/3 pulse pressure). Following these BP measurements, PWV was assessed noninvasively in the supine position following the SphygmoCor® protocol which required an additional 5
reclining BPs immediately before the PWV assessment (AtCor Medical, Sydney, Australia). The PWV technician was trained to a high level of proficiency by a cardiologist who, as part of the training, supervised the
procedure. Electrocardiogram-gated carotid and femoral waveforms were recorded using applanation
tonometry. Carotid-femoral path length was measured as the difference between the surface distances
joining: (a) the suprasternal notch, the umbilicus and the femoral pulse, and (b) the suprasternal notch and
the carotid pulse. Carotid-femoral transit time was estimated in 8–10 sequential femoral and carotid waveforms as the average time difference between the onset of the femoral and carotid waveforms. The foot of
the pulse wave was identified using the intersecting tangent method. The distance measurements were
entered into the software in millimeters. Carotid-femoral PWV was calculated as the carotid-femoral path
length divided by the carotid-femoral transit time, and expressed in meters per second. This is an established,
widely employed, non-invasive and reproducible method to determine arterial stiffness [33]. The coefficient
of variation (1.79%) for serial measurements of PWV in our laboratory indicates high reproducibility of the
PWV measurements.
Demographics and Physical Health Assessment
Demographic, socioeconomic and lifestyle characteristics were obtained from the Nutrition and Health
Questionnaire [30, 31]. Data obtained included smoking history, marital status and medical history. Physical
activity was measured with the Nurses’ Health Study Activity Questionnaire, a validated measure of time
spent engaging in various physical activities [34]. Education level was obtained through self-report and
ranged from 4 to 20 years.
Standard assay methods were employed [35] to obtain fasting plasma glucose (mg/dl), total cholesterol
(mg/dl), low-density lipoprotein cholesterol (LDL, mg/dl), high-density lipoprotein cholesterol (HDL, mg/
dl), triglycerides (mg/dl) and C-reactive protein (mg/l), following an overnight fast. Body weight was
measured with participants wearing light clothing to the nearest 0.1 kg, and height was measured with a
vertical ruler to the nearest 0.1 cm. Body mass index (BMI) was calculated as weight in kilograms divided by
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height in meters squared. Waist circumference (in centimeters) was taken over light clothing using a nonextendable measuring tape, at the level of the iliac crest. Diabetes mellitus was defined as a fasting glucose
level of ≥126 mg/dl, or being treated with antidiabetic medication, obesity as BMI ≥30, and CVD was based
upon self-reported history of coronary artery disease, myocardial infarction, congestive heart failure, transient ischemic attack or angina pectoris, confirmed by medical records.
Statistical Analyses
Participant demographics, health and dietary variables, and BP measures were compared according to
chocolate consumption (<1 serve/week, 1 serve per week, >1 serve/week). Independent samples t tests
were used for continuous variables and χ2 for categorical variables for the analyses involving demographic
variables.
Analysis of variance (categorical regression analyses) was used to relate chocolate intakes with PWV
using three covariate models. After eliminating CVD variables unrelated to both chocolate intake and PWV,
the following models were employed to adjust for confounding in the primary analysis:
Model 1 – Basic: age (years) + gender + education (years) + ethnicity;
Model 2 – PWV model: Basic + heart rate (bpm) + MAP (mm Hg) + height (cm) + weight (kg);
Model 3 – Full model: Basic + PWV model + smoking (cigarettes/day), physical activity (MET hours/
week), total cholesterol (mg/dl), LDL cholesterol (mg/dl), diabetes mellitus, CVD, estimated energy intake
(total daily intakes of all food groups as previously described), intakes of alcohol, meats, vegetables and dairy
foods (all serves/day).
The predictor and the covariates were taken from wave 6 data (prospectively). The PWV-related variables in Model 2 (heart rate, height, weight and MAP) were taken from wave 7 as it is essential that they be
taken at the time of PWV assessment.
Analysis of variance (SPSS) was employed to compare mean values for the three chocolate intake groups.
Linear and quadratic trend analyses across values for the groups were performed when the omnibus test was
statistically significant at α = 0.05, in addition to individual contrasts between the groups. Distributional
requirements were met. All statistical analyses were performed with the PASW for Windows® version 21.0
software (formerly SPSS Statistics; SPSS Inc. Chicago, Ill., USA); p < 0.05 was considered statistically significant.

Results

Participant Characteristics and Chocolate Consumption
Table 1 shows the demographic and health-related variables, PWV and dietary intakes
for MSLS participants (n = 508) according to chocolate consumption (<1 serve/week, 1 serve
per week, >1 serve/week). A significantly higher proportion of women than men consumed
chocolate more than once per week. Those who consumed chocolate more frequently also
had greater intakes of total meats, vegetables and dairy foods, and total energy intakes, but
consumed significantly less alcohol. The levels of total cholesterol and LDL cholesterol
increased significantly across the three chocolate intake categories, but fasting plasma glucose
levels decreased.
Preliminary Test of Interactions
Preliminary tests for interactions (multiplicative effects) with age, sex, BMI and diabetes
were done prior to determining the final models. In each case, the main effect of the risk factor
was included in the model with the interaction term, and the Basic model was employed.
Interaction tests were not statistically significant (p > 0.05).
Main Analyses: Chocolate Consumption and Arterial Stiffness in the MSLS
Table 2 shows the associations between chocolate intake at wave 6 and PWV at wave 7.
The omnibus comparisons among PWV means for the three chocolate intake groups, and the
tests of quadratic trend across the three PWV means, were all statistically significant for all
three models (p < 0.01).
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Table 1. Baseline demographic, health and PWV factors according to chocolate intake in the MSLS sample (n = 508)

Variable

Chocolate intake

p value

<1 serve/week
(n = 174, 34.3%)

1 serve/week
(n = 141, 27.8%)

>1 serve/week
(n = 193, 38.0%)

Age, years
Education, years
Smoking, cigarettes/day
BMI
Physical activity, MET-h/week
Total cholesterol, mg/dl
HDL cholesterol, mg/dl
LDL cholesterol, mg/dl
SBP, mm Hg
DBP, mm Hg
Fasting blood glucose, mg/dl
Triglycerides, mg/dl
C-reactive protein, mg/l

61.6 ± 11.4
14.7 ± 2.9
2.1 ± 6.7
29.5 ± 6.4
18.5 ± 22.4
198.4 ± 42.0
54.7 ± 16.7
118.0 ± 35.8
130.8 ± 21.3
69.9 ± 9.9
102.1 ± 36.6
143.8 ± 133.0
0.37 ± 0.38

61.9 ± 11.9
14.5 ± 2.6
1.0 ± 4.8
29.8 ± 6.4
21.4 ± 22.8
200.4 ± 32.4
54.3 ± 14.3
120.5 ± 30.6
130.5 ± 23.0
70.4 ± 10.3
96.6 ± 24.2
134.2 ± 99.8
0.40 ± 0.48

59.8 ± 11.5
15.0 ± 2.6
1.0 ± 4.3
28.8 ± 5.0
22.6 ± 29.0
209.4 ± 4.8
55.5 ± 15.8
127.7 ± 33.2
126.4 ± 19.5
69.2 ± 9.3
95.2 ± 17.5
131.5 ± 97.0
0.45 ± 0.41

0.2
0.2
0.09
0.3
0.3
0.02
0.8
0.02
0.09
0.5
0.04
0.6
0.3

PWV-related variables (at wave 7)
PWV, m/s
Pulse pressure, mm Hg
Augmentation index, %
Heart rate, bpm
MAP, mm Hg
Height, cm
Weight, kg

11.2 ± 3.5
54.2 ± 16.7
33.1 ± 10.1
60.1 ± 9.4
95.1 ± 11.4
168.3 ± 9.7
83.5 ± 19.9

10.2 ± 2.5
53.9 ± 15.8
32.7 ± 9.7
59.6 ± 9.8
96.0 ± 13.1
167.7 ± 11.7
85.1 ± 20.1

10.3 ± 3.0
51.3 ± 15.8
33.3 ± 10.1
60.2 ± 8.7
93.3 ± 11.5
166.1 ± 9.7
79.5 ± 16.6

0.004
0.2
0.5
0.8
0.1
0.1
0.02

3.7 ± 2.1
1.9 ± 0.8
1.5 ± 1.0
2.6 ± 1.2
1.9 ± 1.0
45.6 ± 75.6

4.0 ± 2.0
2.1 ± 0.9
1.7 ± 1.0
2.9 ± 1.1
1.9 ± 1.1
30.3 ± 50.4

3.7 ± 1.0
2.2 ± 0.9
1.6 ± 0.9
2.8 ± 1.2
2.1 ± 1.2
25.8 ± 44.2

0.4
0.007
0.2
0.05
0.05
0.004

13.9 ± 4.1

15.1 ± 4.8

15.6 ± 4.2

0.001

Dietary variables
Total grains, serves/day
Total meats, serves/day
Total fruit, serves/day
Total vegetables, serves/day
Total dairy foods, serves/day
Alcohol, g/week
Total intake, total serves/day
all food groups
Gender
Male
Female

0.002
81 (46.6)
93 (53.4)

64 (45.4)
77 (54.6)

58 (30.1)
135 (69.9)

Ethnicity
African-American
Other

19 (10.9)
155 (89.1)

11 (7.8)
130 (92.2)

8 (4.1)
185 (95.9)

CVDa
Diabetes mellitusb
Obesityc

57 (16.9)
59 (17.5)
131 (39.5)

29 (10.9)
31 (11.7)
106 (40.9)

53 (14.3)
31 (8.4)
132 (36.2)

0.047

0.1
0.001
0.4

Data are presented as mean ± SD or n (%). All variables taken at wave 6, with the exception of PWV-related variables, taken
from wave 7. p values were obtained by analysis of variance for continuous variables or the χ2 test for categorical variables.
a Based upon self-reported history of coronary artery disease, myocardial infarction, congestive heart failure, transient ischemic
attack, or angina pectoris, confirmed by medical records. b Defined as fasting glucose level of ≥126 mg/dl, or being treated with
antidiabetic medication. c Defined as BMI ≥30.
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Table 2. Multivariate-adjusted means ± standard error for PWV according to chocolate intake (n = 508) at wave 6, predicting
wave 7 PWV

Model

<1 serve/week
(n = 174, 34.3%)

1 serve/week
(n = 141, 27.8%)

>1 serve/week
(n = 193, 38.0%)

Model R2

p overall

p quadratic
trend

Basica
Model 2b
Model 3c

11.0 ± 0.18**
11.0 ± 0.18***
11.0 ± 0.18***

10.0 ± 0.22
10.0 ± 0.19
10.0 ± 0.19

10.6 ± 0.19*
10.7 ± 0.17**
10.7 ± 0.17*

0.316
0.457
0.508

0.002
<0.0001
0.002

0.002
<0.0001
0.001

* p < 0.05, ** p < 0.01, *** p < 0.0001, significantly different from the 1 serve/week group. a Basic model: adjusted for age,
education, gender, ethnicity. b Model 2: adjusted for Basic covariates + height, weight, heart rate, MAP (all at wave 7). c Model
3: adjusted for Basic + Model 2 covariates + smoking, physical activity, total cholesterol, LDL cholesterol, diabetes, CVD, intakes
of total alcohol, meats, vegetables, dairy foods and total energy.

Those who never or rarely ate chocolate (less than once per week) had the highest PWV
of the three consumption groups. The mean PWV of 11 m/s observed in this consumption
group is above reported normative mean values in both men and women [15]. Participants
who consumed chocolate once per week had significantly lower PWV than those who
consumed chocolate less frequently (never or seldom) and more frequently (more than once
per week) than this (p values <0.05). This pattern of results was significant for the Basic
model and remained with the addition of PWV-related variables (Model 2, p < 0.0001). Similarly, there was no attenuation observed with the addition of multiple cardiovascular risk
factors and dietary variables to the model (Model 3, p = 0.002).
Attrition
In order to evaluate the effects of attrition on the results, health variable values for
those who were participants at both wave 6 and wave 7 were compared with values for
participants who did not return for wave 7 testing. Those who dropped out of the study
were older, exhibited more depressive symptoms, had higher SBP and DBP, and lower HDL
cholesterol (all p < 0.05, data not shown). However, there was no significant difference in
chocolate intakes between those who did and did not complete wave 7 testing (p = 0.3, data
not shown).
Tests of Interactions and Sensitivity Analyses
The PWV-related variables taken from wave 7 in Model 2 (heart rate, height, weight and
MAP) were taken from wave 6 in a sensitivity analysis, and the results remain unchanged.
Moreover, when weight and height (from wave 7) were replaced with waist circumference
and then BMI (from wave 7), similarly, no change in the results was observed. In additional
sensitivity analyses, replacing diabetes with fasting plasma glucose in Model 3 did not change
the results, nor did the addition of triglycerides to the final model. We performed further
analyses excluding both those with diabetes and CVD, and the results remained unchanged.
The same significant non-linear findings were observed when we stratified the sample
according to obesity status (BMI <30 and ≥30). Results were the same for the obese and nonobese groups. Further, replacing MAP (at wave 7) with SBP and DBP (taken at wave 7) did
not alter the results, and reanalyses following stratification according to sex did not change
the pattern of results.
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Discussion

In this prospective study, chocolate intake was significantly associated with PWV in a
non-linear fashion. Those who never or rarely consumed chocolate had the highest PWV.
Those with a moderate chocolate intake (once per week) had significantly lower mean PWV
values than those who never or rarely consumed chocolate, and those who consumed more
frequently than once per week. Importantly, this pattern remained significant after adjustment
for a number of cardiovascular risk factors, physical activity, smoking, CVD and diabetes
mellitus. Associations were not attenuated with the addition of dietary variables (alcohol,
meats, vegetables and dairy foods), indicating that chocolate may be associated with arterial
stiffness, irrespective of other dietary habits. Although there was a statistically significant
difference between the moderate intake group (1 serve/week) and the highest intake group
(>1 serve/week), the difference is not of notable clinical importance in terms of the magnitude
of the difference between the two groups [15].
Our findings are consistent with previous studies. A higher cocoa intake (from dark and
milk chocolate) was associated with lower PWV in a cross-sectional study of 198 adults [21],
one of the first studies to suggest that habitual cocoa consumption (from chocolate) may be
associated with lower arterial stiffness. Vlachopoulous et al. [21] showed that the lowest PWV
(mean 6.2 ± 1.2 m/s) was observed in those with low cocoa intakes (<4.63 g cocoa/day), and
PWV was higher in both the non-consumer group (mean 7.0 ± 6.2 m/s) and the high consumption
(≥4.63 g cocoa/day) group (mean 6.9 ± 1.0 m/s), which is in line with our results.
A more recent cross-sectional study of 351 adults from a primary care setting with some
cardiovascular risk factors (hypertension, diabetes or dyslipidemia) showed that higher PWV
was higher in non-cocoa consumers as compared to high consumers (>1 serving/week);
however, these differences were no longer significant following adjustment for age, sex,
presence of diabetes, SBP and use of antihypertensive and lipid-lowering drugs [20]. It is
unknown whether a threshold effect as in our study may have been observed in the study by
Recio-Rodriguez et al. [20] as there was no further classification of cocoa consumers beyond
more than one serving per week. Findings from dietary intervention studies have also been
mixed. In a randomized, cross-over study, Vlachopoulous et al. [23] examined the immediate
effects of the consumption of 100 g of dark chocolate in 17 young healthy adults and found
no significant change in PWV, despite increased flow-mediated dilation. In contrast, West et
al. [24] examined the effect of daily cocoa and dark chocolate consumption (22 g/day of
natural cocoa) for 4 weeks on endothelial function and arterial stiffness in 30 overweight
adults in a placebo-controlled, randomized, crossover study. Significant reductions in
peripheral arterial stiffness were observed in women only. Pereira et al. [36] reported that
the consumption of 10 g of dark chocolate daily for 1 month in 30 young, healthy individuals
significantly decreased aortic PWV compared to a control group. In a subsequent study, Grassi
et al. [22] reported that cocoa dose-dependently decreased PWV following daily intakes of
cocoa (with differing quantities of cocoa flavonoids) over a 1-week period. In contrast to
these studies, another placebo-controlled, 3-week cross-over trial in 42 healthy adults showed
that a theobromine-enriched cocoa powder drink increased PWV, but decreased central SBP
[25]. However, these short-term dietary intervention studies are difficult to interpret in terms
of clinical and public health relevance since atherosclerosis and CVD are chronic conditions;
therefore, their natural history is more likely to be affected by long-term exposures.
The possible beneficial actions of cocoa on BP have largely been attributed to flavanols
and their antioxidant properties, mainly by improving nitric oxide bioavailability [10, 37, 38].
Flavanols and their metabolites may reduce BP by angiotensin-converting enzyme inhibition
[39], nicotinamide adenine dinucleotide phosphate-oxidase activity inhibition [40] and stimulating the release of nitric oxide [10]. The anti-inflammatory properties of cocoa may also

35

Pulse 2016;4:28–37
DOI: 10.1159/000445876

© 2016 S. Karger AG, Basel
www.karger.com/pls

Crichton et al.: Relation of Habitual Chocolate Consumption to Arterial Stiffness in a
Community-Based Sample: Preliminary Findings

play a role as inflammation is associated with increased arterial stiffness [41]. Additionally,
theobromine, present in cocoa in high concentrations, could also contribute to the antihypertensive effect of cocoa [42, 43], as it is thought to have vasodilating properties by inhibiting
phosphodiesterase [44].
Several limitations of the present study must be acknowledged. Chocolate intake was selfreported, and therefore subject to inherent reporting error. The dietary questionnaire used
did not require the respondent to differentiate between dark, milk or white chocolate. Most
clinical trials have used dark chocolate as the source of cocoa flavanols. In 2012, the distribution share of chocolate in the United States by favorite chocolate type was 57% milk chocolate, 35% dark chocolate and 8% white chocolate [1]. We can therefore make the assumption
that the majority of chocolate consumed in this sample was dark or milk, both containing cocoa
flavanols to varying degrees. We are unable to calculate the actual quantities of chocolate and
cocoa associated with higher or lower PWV due to the nature of the questionnaire. There are
a number of reasons why a linear dose-response relationship was not observed. There are
many examples in medicine whereby a low dose may be equally or more effective than a high
dose; for example, the use of low-dose aspirin in preventing future stroke [45]. Secondly, there
may be components in chocolate that may ‘override’ the potentially beneficial effects from
small intakes. Clearly, further studies are needed, particularly longitudinal studies and clinical
trials in which specific quantities of chocolate, across a wider range of consumption levels are
investigated to estimate optimal quantities associated with cardiovascular benefits.
We were able to statistically control for a number of cardiovascular, lifestyle and dietary
variables that may impact upon a relationship between habitual chocolate consumption and
arterial stiffness. Interestingly, with the addition of these variables to the model, the multivariable adjusted mean PWV for the highest chocolate intake group increased (from an unadjusted 10.3 to 10.7 m/s in Model 3). There was less change in the lower intake groups; for the
non-consumer, the mean PWV of 11.2 m/s became 11.0 m/s after adjustment, and for the
moderate consumer group, the mean PWV of 10.3 m/s became 10.0 m/s after adjustment. We
speculate that this may relate to the ranges of intake levels within each group. For example, in
the lowest consumption group, intakes ranged from 0 to 0.5 serves per week. However, the
highest consumption group had intakes ranging from 1.9 to 7 serves per week. Perhaps the
multivariable adjustment may have had a larger effect on this group due to the wider range of
intakes. This reinforces the need for further studies examining a wider range of chocolate intakes.
This is the first longer-term study (5 years) that we are aware of to show that chocolate
consumption in adults may impact upon measures of arterial stiffness up to 5 years later. Our
study also had a larger sample size than previous observational studies [20, 21], which may
contribute to the different findings.
Conclusion

Large artery stiffness plays a causal role in systolic hypertension and is an independent
marker of cardiovascular risk. The present findings support recent clinical trials and other
cross-sectional research suggesting that a regular intake of a moderate amount of chocolate
may have a beneficial effect on arterial stiffness. These relationships were independent of
cardiovascular risk factors, diabetes, BMI and other dietary factors. Our findings are novel in
that they are suggestive of a threshold effect, whereby chocolate in moderate amounts may
be more beneficial than not consuming any chocolate, but higher intakes may not. The findings
suggest that future studies are warranted to investigate optimal quantities of chocolate/
cocoa consumption to produce short or longer-term effects while taking into account overall
dietary patterns.
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